ArticleMelanoma research2021

A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.

Jackee N Sanchez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.